グローバルにおける子宮頸がん治療薬市場及びパイプライン分析...市場調査レポートについてご紹介

1. Cervical Cancer Drug Market Overview
1.1 Market Overview
1.2 Clinical Pipeline Insight

2. Cervical Cancer Drug Clinical Trial Insight by Phase & Country
2.1 Preclinical
2.2 Clinical
2.3 Phase I
2.4 Phase I/II
2.5 Phase II
2.6 Phase III

3. Marketed Cervical Cancer Drug Clinical Insight & Patent Analysis

4. Discontinued & No Development Reported in Cervical Cancer Drug
4.1 No Development Reported
4.2 Discontinued

5. Competitive Landscape
5.1 Advaxis
5.2 ApoVax
5.3 Genentech
5.4 GlaxoSmithKline
5.5 Inovio Pharmaceuticals
5.6 ISA Pharmaceuticals
5.7 Kaken Pharmaceutical
5.8 Merck

Figure 1- 1: US – Number Cervical Cancer New Cases & Deaths, 2014
Figure 1- 2: Global Cervical Cancer Market (US$), 2013-2020
Figure 1- 3: Cervical Cancer Drugs in Pipeline by Phase (%), 2014
Figure 1- 4: Number of Cervical Cancer Drugs in Pipeline by Phase, 2014
Figure 1- 5: No Development in Cervical Cancer Drugs in Pipeline by Phase (%), 2014
Figure 1- 6: No Development in Cervical Cancer Drugs in Pipeline by Phase (Number), 2014
Figure 1- 7: Discontinued Cervical Cancer Drugs in Pipeline by Phase (%), 2014
Figure 1- 8: Number of Discontinued Cervical Cancer Drugs in Pipeline by Phase (%), 2014

Table 1-1: Europe – Cervical Cancer Estimated Incidence & Mortality by country, 2012

Following Information for Each Drug Profile is Covered in More than 200 Tables in Report:

• Drug Profile Overview
• Active Indication
• Phase of Development
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route
• Drug Class